Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4333)
All Articles published online
|
Mar 15, 2003 (publication date) through Feb 14, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y, Li CL, Meng FJ. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive traet. World J Gastroenterol 2003; 9(3): 495-498 [PMID: PMC4621568 DOI: 10.3748/wjg.v9.i3.495] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v9/i3/495.htm |
| Number | Citing Articles |
| 1 |
Manik Amin, Albert Craig Lockhart. The potential role of immunotherapy to treat colorectal cancer. Expert Opinion on Investigational Drugs 2015; 24(3): 329 doi: 10.1517/13543784.2015.985376
|
| 2 |
Zheng Lv, Tian-Yuan Zhang, Jie-Chao Yin, Hui Wang, Tian Sun, Li-Qun Chen, Fu-Liang Bai, Wei Wu, Gui-Ping Ren, De-Shan Li. Enhancement of Anti-tumor Activity of Newcastle Disease Virus by the Synergistic Effect of Cytosine Deaminase. Asian Pacific Journal of Cancer Prevention 2013; 14(12): 7489 doi: 10.7314/APJCP.2013.14.12.7489
|
| 3 |
Ying An, Tianyan Liu, Jinjiao He, Hongsong Wu, Rui Chen, Yunye Liu, Yunzhou Wu, Yin Bai, Xiaochen Guo, Qi Zheng, Chang Liu, Jiechao Yin, Deshan Li, Guiping Ren. Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model. Journal of Biomedical Science 2016; 23(1) doi: 10.1186/s12929-016-0273-0
|
| 4 |
Volker Schirrmacher. Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!. Biomedicines 2016; 4(3): 16 doi: 10.3390/biomedicines4030016
|
| 5 |
Shuang Chen, Qinggao Zhang, Duo Xu, Yiquan Li, Yuanyuan Fan, Wenjie Li, Xunzhe Yin, Yang Zhang, Jingwei Liu, Xiao Li, Lili Sun, Ningyi Jin. Antitumor effect of the Newcastle disease viral hemagglutinin–neuraminidase gene is expressed through an oncolytic adenovirus effect in osteosarcoma cells. Anti-Cancer Drugs 2018; 29(3): 197 doi: 10.1097/CAD.0000000000000575
|
| 6 |
Kenneth Lundstrom. Viral Vectors in Gene Therapy. Diseases 2018; 6(2): 42 doi: 10.3390/diseases6020042
|
| 7 |
Kenneth Lundstrom. Handbook of Cancer and Immunology. 2022; : 1 doi: 10.1007/978-3-030-80962-1_198-1
|
| 8 |
Stefan K. Burgdorf, Hans J. Nielsen, Jacob Rosenberg. Immunotherapy in colorectal cancer. Scandinavian Journal of Gastroenterology 2009; 44(3): 261 doi: 10.1080/00365520802400909
|
| 9 |
Benqiang Rao, Minyan Han, Lei Wang, Xiaoyan Gao, Jun Huang, Meijin Huang, Huanliang Liu, Jianping Wang. Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. Journal of Translational Medicine 2011; 9(1) doi: 10.1186/1479-5876-9-17
|
| 10 |
Michael Morse, Lee Langer, Alexander Starodub, Amy Hobeika, Timothy Clay, H. Kim Lyerly. Current Immunotherapeutic Strategies in Colon Cancer. Surgical Oncology Clinics of North America 2007; 16(4): 873 doi: 10.1016/j.soc.2007.07.005
|
| 11 |
Moumita Mondal, Jingao Guo, Ping He, Dongming Zhou. Recent advances of oncolytic virus in cancer therapy. Human Vaccines & Immunotherapeutics 2020; 16(10): 2389 doi: 10.1080/21645515.2020.1723363
|
| 12 |
Kenneth Lundstrom. Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. Viruses 2020; 12(11): 1324 doi: 10.3390/v12111324
|
| 13 |
Vanessa Deschoolmeester, Evelien Smits, Marc Peeters, Jan B. Vermorken. Status of Active Specific Immunotherapy for Stage II, Stage III, and Resected Stage IV Colon Cancer. Current Colorectal Cancer Reports 2013; 9(4): 380 doi: 10.1007/s11888-013-0182-5
|
| 14 |
Bharat Burman, Giulio Pesci, Dmitriy Zamarin. Newcastle Disease Virus at the Forefront of Cancer Immunotherapy. Cancers 2020; 12(12): 3552 doi: 10.3390/cancers12123552
|
| 15 |
Paul G. Toomey, Nasreen A. Vohra, Tomar Ghansah, Amod A. Sarnaik, Shari A. Pilon-Thomas. Immunotherapy for Gastrointestinal Malignancies. Cancer Control 2013; 20(1): 32 doi: 10.1177/107327481302000106
|
| 16 |
Dmitriy Zamarin, Peter Palese. Oncolytic Newcastle Disease Virus for Cancer Therapy: Old Challenges and New Directions. Future Microbiology 2012; 7(3): 347 doi: 10.2217/fmb.12.4
|
| 17 |
Fang Huang, Chuanjing Dai, Youni Zhang, Yuqi Zhao, Yigang Wang, Guoqing Ru. Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy. Frontiers in Molecular Biosciences 2022; 9 doi: 10.3389/fmolb.2022.889403
|
| 18 |
Dmitriy Zamarin, Luis Martínez-Sobrido, Kaitlyn Kelly, Mena Mansour, Gang Sheng, Adam Vigil, Adolfo García-Sastre, Peter Palese, Yuman Fong. Enhancement of Oncolytic Properties of Recombinant Newcastle Disease Virus Through Antagonism of Cellular Innate Immune Responses. Molecular Therapy 2009; 17(4): 697 doi: 10.1038/mt.2008.286
|
| 19 |
Kenneth Lundstrom. RNA Viruses as Tools in Gene Therapy and Vaccine Development. Genes 2019; 10(3): 189 doi: 10.3390/genes10030189
|
| 20 |
P. O. Vorobyev, F. E. Babaeva, A. V. Panova, J. Shakiba, S. K. Kravchenko, A. V. Soboleva, A. V. Lipatova. Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases. Molecular Biology 2022; 56(5): 684 doi: 10.1134/S0026893322050144
|
| 21 |
M Janke, B Peeters, O de Leeuw, R Moorman, A Arnold, P Fournier, V Schirrmacher. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Therapy 2007; 14(23): 1639 doi: 10.1038/sj.gt.3303026
|
| 22 |
Kenneth Lundstrom. Encyclopedia of Infection and Immunity. 2022; : 763 doi: 10.1016/B978-0-12-818731-9.00137-3
|
| 23 |
|
| 24 |
Sheela Onnockx, Aline Baldo, Katia Pauwels. Oncolytic Viruses: An Inventory of Shedding Data from Clinical Trials and Elements for the Environmental Risk Assessment. Vaccines 2023; 11(9): 1448 doi: 10.3390/vaccines11091448
|
| 25 |
Ann Willman Silk, Olivera J Finn. Cancer Vaccines: A Promising Cancer Therapy Against All Odds. Future Oncology 2007; 3(3): 299 doi: 10.2217/14796694.3.3.299
|
| 26 |
D Zamarin, A Vigil, K Kelly, A García-Sastre, Y Fong. Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Therapy 2009; 16(6): 796 doi: 10.1038/gt.2009.14
|
| 27 |
Frank M Speetjens, Eliane CM Zeestraten, Peter JK Kuppen, Cornelis JM Melief, Sjoerd H van der Burg. Colorectal cancer vaccines in clinical trials. Expert Review of Vaccines 2011; 10(6): 899 doi: 10.1586/erv.11.63
|
| 28 |
Jun-Xia Cao, Xiao-Yan Zhang, Jin-Long Liu, Jun-Li Li, Yi-Shan Liu, Min Wang, Bei-Lei Xu, Zheng-Xu Wang. Validity of combination active specific immunotherapy for colorectal cancer: a meta-analysis of 2993 patients. Cytotherapy 2015; 17(12): 1746 doi: 10.1016/j.jcyt.2015.08.009
|
| 29 |
Patrycja J Lech, Stephen J Russell. Use of attenuated paramyxoviruses for cancer therapy. Expert Review of Vaccines 2010; 9(11): 1275 doi: 10.1586/erv.10.124
|
| 30 |
Volker Schirrmacher. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunology, Immunotherapy 2005; 54(6): 587 doi: 10.1007/s00262-004-0602-0
|
| 31 |
|
| 32 |
Huijie Bian, Philippe Fournier, Rob Moormann, Ben Peeters, Volker Schirrmacher. Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. Cancer Gene Therapy 2005; 12(3): 295 doi: 10.1038/sj.cgt.7700774
|
| 33 |
Xiaoyong Fan, Hongzhen Lu, Youqiang Cui, Xianzeng Hou, Chuanjiang Huang, Guangcun Liu. Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway. Experimental and Therapeutic Medicine 2018; doi: 10.3892/etm.2018.5935
|
| 34 |
Benjamin Levy, John F. Deeken, Greg Holt, John L. Marshall. Immunologic Therapies for Gastrointestinal Cancers. Clinical Colorectal Cancer 2005; 5(1): 37 doi: 10.3816/CCC.2005.n.015
|
| 35 |
Fang Huang, Bin-Rong Wang, Ye-Qing Wu, Fan-Chao Wang, Jian Zhang, Yi-Gang Wang. Oncolytic viruses against cancer stem cells: A promising approach for gastrointestinal cancer. World Journal of Gastroenterology 2016; 22(35): 7999-8009 doi: 10.3748/wjg.v22.i35.7999
|
| 36 |
Kenneth Lundstrom. The Biological Role of a Virus. Advances in Environmental Microbiology 2022; 9: 285 doi: 10.1007/978-3-030-85395-2_9
|
| 37 |
Huiming Yang, Jiaxin Tian, Jing Zhao, Ye Zhao, Guozhong Zhang. The Application of Newcastle Disease Virus (NDV): Vaccine Vectors and Tumor Therapy. Viruses 2024; 16(6): 886 doi: 10.3390/v16060886
|
| 38 |
Chin Liang Lee, Sanggeetha Veeramani, Aidin Molouki, Swee Hua Erin Lim, Warren Thomas, Suet Lin Chia, Khatijah Yusoff. Virotherapy: Current Trends and Future Prospects for Treatment of Colon and Rectal Malignancies. Cancer Investigation 2019; 37(8): 393 doi: 10.1080/07357907.2019.1660887
|
| 39 |
Szilvia Mosolits, Bo Nilsson, Håkan Mellstedt. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Review of Vaccines 2005; 4(3): 329 doi: 10.1586/14760584.4.3.329
|
| 40 |
Altijana Hromic-Jahjefendic, Kenneth Lundstrom. Viral Vector-Based Melanoma Gene Therapy. Biomedicines 2020; 8(3): 60 doi: 10.3390/biomedicines8030060
|
| 41 |
Volker Schirrmacher. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance. Expert Opinion on Biological Therapy 2015; 15(12): 1757 doi: 10.1517/14712598.2015.1088000
|
| 42 |
Han Yuen Lam, Swee Keong Yeap, Mehdi Rasoli, Abdul Rahman Omar, Khatijah Yusoff, Abd Aziz Suraini, Noorjahan Banu Alitheen, Thomas Griffith. Safety and Clinical Usage of Newcastle Disease Virus in Cancer Therapy. BioMed Research International 2011; 2011(1) doi: 10.1155/2011/718710
|
| 43 |
Ziye Pan, Jinjiao He, Lubna M. Rasoul, Yunye Liu, Ruixiang Che, Yun Ding, Xiaocheng Guo, Jiarui Yang, Dehua Zou, Hua Zhang, Deshan Li, Hongwei Cao, Man-Seong Park. Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor Effect. PLOS ONE 2016; 11(10): e0164723 doi: 10.1371/journal.pone.0164723
|
| 44 |
M. M. Zulkifli, R. Ibrahim, A. M. Ali, I. Aini, H. Jaafar, S. S. Hilda, N. B. Alitheen, J. M. Abdullah. Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma. Neurological Research 2009; 31(1): 3 doi: 10.1179/174313208X325218
|
| 45 |
Volker Schirrmacher, Philippe Fournier, Peter Schlag. Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Expert Review of Vaccines 2014; 13(1): 117 doi: 10.1586/14760584.2014.854169
|
| 46 |
Sung Hoon Jang, Bo-Kyoung Jung, Yong Hee An, Hyun Jang. The phosphatase and tensin homolog gene inserted between NP and P gene of recombinant Newcastle disease virus oncolytic effect test to glioblastoma cell and xenograft mouse model. Virology Journal 2022; 19(1) doi: 10.1186/s12985-022-01746-w
|
| 47 |
Dirk Nagorsen, Eckhard Thiel. Clinical and Immunologic Responses to Active Specific Cancer Vaccines in Human Colorectal Cancer. Clinical Cancer Research 2006; 12(10): 3064 doi: 10.1158/1078-0432.CCR-05-2788
|
| 48 |
Philippe Fournier, Volker Schirrmacher. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Expert Review of Vaccines 2009; 8(1): 51 doi: 10.1586/14760584.8.1.51
|
| 49 |
David Tougeron, Émilie Fauquembergue, Jean-Baptiste Latouche. Stratégies d’immunothérapie dans les cancers colorectaux. Bulletin du Cancer 2013; 100(9): 871 doi: 10.1684/bdc.2013.1800
|
| 50 |
Razvan Zdrehus, Cristian Delcea, Lucian Mocan. Role of Biofunctionalized Nanoparticles in Digestive Cancer Vaccine Development. Pharmaceutics 2024; 16(3): 410 doi: 10.3390/pharmaceutics16030410
|
| 51 |
Lixiang Zhao, Yu Mei, Qing Sun, Linghua Guo, Yan Wu, Xiao Yu, Bo Hu, Xiufan Liu, Haiyan Liu. Autologous Tumor Vaccine Modified with Recombinant New Castle Disease Virus Expressing IL-7 Promotes Antitumor Immune Response. The Journal of Immunology 2014; 193(2): 735 doi: 10.4049/jimmunol.1400004
|
| 52 |
Fu-Liang Bai, Yin-Hang Yu, Hui Tian, Gui-Ping Ren, Hui Wang, Bing Zhou, Xiao-Hui Han, Qing-Zhong Yu, De-Shan Li. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Cancer Biology & Therapy 2014; 15(9): 1226 doi: 10.4161/cbt.29686
|
| 53 |
Anton Oseledchyk, Jacob M. Ricca, Mathieu Gigoux, Brian Ko, Gil Redelman-Sidi, Tyler Walther, Cailian Liu, Gopa Iyer, Taha Merghoub, Jedd D. Wolchok, Dmitriy Zamarin. Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget 2018; 9(47): 28702 doi: 10.18632/oncotarget.25614
|
| 54 |
|
| 55 |
Rajiv Kumar, Ashok K. Tiwari, Uttara Chaturvedi, G. Ravi Kumar, Aditya P. Sahoo, R. S. Rajmani, Lovleen Saxena, Shikha Saxena, Sangeeta Tiwari, Sudesh Kumar. Velogenic Newcastle Disease Virus as an Oncolytic Virotherapeutics: In Vitro Characterization. Applied Biochemistry and Biotechnology 2012; 167(7): 2005 doi: 10.1007/s12010-012-9700-1
|
| 56 |
S. Mosolits, G. Ullenhag, H. Mellstedt. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Annals of Oncology 2005; 16(6): 847 doi: 10.1093/annonc/mdi192
|
| 57 |
Matthew McKinney, Michael A. Morse. Advances in immunotherapy for colorectal malignancies. Current Colorectal Cancer Reports 2008; 4(4): 177 doi: 10.1007/s11888-008-0029-7
|
| 58 |
Aniruddha Choudhury, Szilvia Mosolits, Parviz Kokhaei, Lotta Hansson, Marzia Palma, Håkan Mellstedt. . Advances in Cancer Research 2006; 95: 147 doi: 10.1016/S0065-230X(06)95005-2
|
| 59 |
Gerben J. van der Bij, Steven J. Oosterling, Robert H. J. Beelen, Sybren Meijer, John C. Coffey, Marjolein van Egmond. The Perioperative Period is an Underutilized Window of Therapeutic Opportunity in Patients With Colorectal Cancer. Annals of Surgery 2009; 249(5): 727 doi: 10.1097/SLA.0b013e3181a3ddbd
|
| 60 |
Fuliang Bai, Zeshan Niu, Hui Tian, Siming Li, Zheng Lv, Tianyuan Zhang, Guiping Ren, Deshan Li. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy. Immunology Letters 2014; 159(1-2): 36 doi: 10.1016/j.imlet.2014.02.009
|
| 61 |
Kathy Matuszewska, Lisa A. Santry, Jacob P. van Vloten, Amanda W.K. AuYeung, Pierre P. Major, Jack Lawler, Sarah K. Wootton, Byram W. Bridle, Jim Petrik. Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer. Clinical Cancer Research 2019; 25(5): 1624 doi: 10.1158/1078-0432.CCR-18-0220
|
| 62 |
Volker Schirrmacher, Stefaan van Gool, Wilfried Stuecker. Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy. Biomedicines 2019; 7(3): 66 doi: 10.3390/biomedicines7030066
|
| 63 |
Michael Brown. Cancer Immunotherapies. Cancer Treatment and Research 2022; 183: 91 doi: 10.1007/978-3-030-96376-7_3
|
| 64 |
Sudhir Morla, Ajay Kumar, Sachin Kumar. Newcastle disease virus mediated apoptosis and migration inhibition of human oral cancer cells: A probable role of β-catenin and matrix metalloproteinase-7. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-47244-y
|
| 65 |
Vanessa Deschoolmeester, David Kerr, Patrick Pauwels, Jan B. Vermorken. Immunotherapy for Gastrointestinal Cancer. 2017; : 23 doi: 10.1007/978-3-319-43063-8_2
|
| 66 |
Hui Song, Li-Ping Zhong, Jian He, Yong Huang, Yong-Xiang Zhao. Application of Newcastle disease virus in the treatment of colorectal cancer. World Journal of Clinical Cases 2019; 7(16): 2143-2154 doi: 10.12998/wjcc.v7.i16.2143
|
| 67 |
Judit Svensson-Arvelund, Sara Cuadrado-Castano, Gvantsa Pantsulaia, Kristy Kim, Mark Aleynick, Linda Hammerich, Ranjan Upadhyay, Michael Yellin, Henry Marsh, Daniel Oreper, Suchit Jhunjhunwala, Christine Moussion, Miriam Merad, Brian D. Brown, Adolfo García-Sastre, Joshua D. Brody. Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity. Nature Communications 2022; 13(1) doi: 10.1038/s41467-022-34791-8
|